Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 11/20 | 0.48 |
| ▸ | ATRIP | Q8WXE1 | 11/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27000319 | 0.86 | ATR (0.64) | ATRATRIP | |
| SCHEMBL26998091 | 0.85 | ROCK2 (0.43) | ATRATRIPNTRK1ROCK2 | |
| SCHEMBL26999057 | 0.85 | ATR (0.39) | ATRATRIPNTRK1ROCK2PIM1 | |
| SCHEMBL26998358 | 0.85 | ATR (0.38) | ATRATRIPNTRK1ROCK2 | |
| SCHEMBL27001067 | 0.84 | ATR (0.43) | ATRATRIPROCK2 | |
| SCHEMBL27000901 | 0.84 | ATR (0.41) | ATRATRIPNTRK1ROCK2 | |
| SCHEMBL27000875 | 0.82 | ATR (0.43) | ATRATRIPROCK2 | |
| SCHEMBL27000900 | 0.82 | ATR (0.43) | ATRATRIPROCK2 | |
| SCHEMBL27000337 | 0.82 | ATR (0.38) | ATRATRIPROCK2 | |
| SCHEMBL26737539 | 0.80 | PDPK1 (0.39) | ATRPDPK1TGFBR1AURKBEGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | ATR 277/4885ATRIP 734/4885HRH3 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.